Nature Communications (Jan 2017)
A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis
- Silvia Moretti,
- Giorgia Renga,
- Vasilis Oikonomou,
- Claudia Galosi,
- Marilena Pariano,
- Rossana G. Iannitti,
- Monica Borghi,
- Matteo Puccetti,
- Marco De Zuani,
- Carlo E. Pucillo,
- Giuseppe Paolicelli,
- Teresa Zelante,
- Jean-Christophe Renauld,
- Oxana Bereshchenko,
- Paolo Sportoletti,
- Vincenzina Lucidi,
- Maria Chiara Russo,
- Carla Colombo,
- Ersilia Fiscarelli,
- Cornelia Lass-Flörl,
- Fabio Majo,
- Gabriella Ricciotti,
- Helmut Ellemunter,
- Luigi Ratclif,
- Vincenzo Nicola Talesa,
- Valerio Napolioni,
- Luigina Romani
Affiliations
- Silvia Moretti
- Department of Experimental Medicine, University of Perugia
- Giorgia Renga
- Department of Experimental Medicine, University of Perugia
- Vasilis Oikonomou
- Department of Experimental Medicine, University of Perugia
- Claudia Galosi
- Department of Experimental Medicine, University of Perugia
- Marilena Pariano
- Department of Experimental Medicine, University of Perugia
- Rossana G. Iannitti
- Department of Experimental Medicine, University of Perugia
- Monica Borghi
- Department of Experimental Medicine, University of Perugia
- Matteo Puccetti
- Department of Experimental Medicine, University of Perugia
- Marco De Zuani
- Department of Medical and Biological Science, University of Udine
- Carlo E. Pucillo
- Department of Medical and Biological Science, University of Udine
- Giuseppe Paolicelli
- Department of Experimental Medicine, University of Perugia
- Teresa Zelante
- Department of Experimental Medicine, University of Perugia
- Jean-Christophe Renauld
- Ludwig Institute for Cancer Research, Brussels Branch
- Oxana Bereshchenko
- Department of Medicine, Section of Pharmacology, University of Perugia
- Paolo Sportoletti
- Institute of Haematology-CREO (Centro di Ricerche Emato-Oncologiche), Ospedale S. Maria Misericordia
- Vincenzina Lucidi
- Unit of Endocrinology and Diabetes, Bambino Gesù Children's Hospital
- Maria Chiara Russo
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan
- Carla Colombo
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan
- Ersilia Fiscarelli
- Bambino Gesù Children's Hospital IRCCS
- Cornelia Lass-Flörl
- Division of Hygiene and Medical Microbiology, Innsbruck Medical University
- Fabio Majo
- Unit of Endocrinology and Diabetes, Bambino Gesù Children's Hospital
- Gabriella Ricciotti
- Bambino Gesù Children's Hospital IRCCS
- Helmut Ellemunter
- CF Centre, Medical University Innsbruck
- Luigi Ratclif
- Servizio di Supporto Fibrosi Cistica, Istituto Ospedale G. Tatarella
- Vincenzo Nicola Talesa
- Department of Experimental Medicine, University of Perugia
- Valerio Napolioni
- Department of Experimental Medicine, University of Perugia
- Luigina Romani
- Department of Experimental Medicine, University of Perugia
- DOI
- https://doi.org/10.1038/ncomms14017
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 13
Abstract
In patients with cystic fibrosis, IL-9 signalling is increased. The authors describe an inflammatory loop in which IL-9 produced by Th9 cells drives mast cells to produce IL-2, resulting in ILC2 cell activation, and show inhibition of this loop with blocking antibodies to IL-9 in a mouse model of pulmonary infection.
